Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial.

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.

Arch Drug Inf. 2011 Sep;4(3):33-41.

2.

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial.

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.

Arch Drug Inf. 2010 Sep;3(3):45-53.

3.

Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.

Heras P, Kritikos K, Hatzopoulos A, Mitsibounas D.

Eur J Cancer Care (Engl). 2008 Nov;17(6):619-23. doi: 10.1111/j.1365-2354.2007.00892.x. Epub 2008 Aug 13.

PMID:
18707619
4.

Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.

Gertz B, Kohler E, Kes P, Essaian A, Bias P, Buchner A, Elsässer R.

Curr Med Res Opin. 2010 Oct;26(10):2393-402. doi: 10.1185/03007995.2010.511084.

PMID:
20812790
5.

Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.

Biesma B, van de Werf PR, Melissant CF, Brok RG.

Lung Cancer. 2007 Oct;58(1):104-11. Epub 2007 Jun 29.

PMID:
17601632
6.

Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.

Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D.

Curr Med Res Opin. 2012 Jul;28(7):1101-10. doi: 10.1185/03007995.2012.688736. Epub 2012 May 23.

PMID:
22533679
7.

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.

Cortesi E, Mancuso A, De Pasquale Ceratti A, Pizzardi N, D'Auria G, Accettura C, Beccaglia P, Bertelletti D, De Marinis F.

Oncologist. 2004;9(4):459-68.

9.

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group.

J Clin Oncol. 2001 Jun 1;19(11):2865-74.

PMID:
11387359
10.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly.

Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review.

PMID:
17182241
11.

A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.

Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G.

Anticancer Res. 2005 Jan-Feb;25(1B):669-74.

12.

Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.

Granetto C, Ricci S, Martoni A, Pezzella G, Testore F, Mattioli R, Lampignano M, Tacconi F, Porrozzi S, Gasparini G, Mantovani G; EPO-ITA3 Study Group.

Oncol Rep. 2003 Sep-Oct;10(5):1289-96.

PMID:
12883695
13.

Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.

Oncologist. 2004;9(1):90-6. Erratum in: Oncologist. 2004;9(2):240.

14.

A pilot study to evaluate the safety and clinical outcomes of once-weekly epoetin alfa 80,000 u in anemic patients with cancer receiving chemotherapy.

Waltzman RJ, Williams D, Braly P.

Support Cancer Ther. 2005 Oct 1;3(1):47-53. doi: 10.3816/SCT.2005.n.024.

PMID:
18632436
15.
16.

An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Mustacchi G, Ceccherini R, Dellach C, Foladore S, Milani S, Leita M, Sisto M.

Ann Oncol. 2006 Nov;17(11):1705-8. Epub 2006 Sep 15.

PMID:
16980603
17.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
18.

Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy.

Krzakowski M; DYNEPO Oncology Study Group.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):705-13. doi: 10.1016/j.clon.2008.06.001. Epub 2008 Aug 8.

PMID:
18691854
20.

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.

Dammacco F, Castoldi G, Rödjer S.

Br J Haematol. 2001 Apr;113(1):172-9. Erratum in: Br J Haematol 2001 Sep;114(3):738.

PMID:
11328297

Supplemental Content

Support Center